LEDVANCE, the Makers of SYLVANIA General Lighting, Launches Brighter Days Ahead Campaign

Enter for a Chance to Win $1,000 & SYLVANIA General Lighting Products to Help Brighten Your Day

WILMINGTON, Mass., May 27, 2021 /CNW/ - The year 2020 was difficult for all of us. With vaccines rolling out and businesses opening though, brighter days are ahead. To celebrate this light at the end of the tunnel, LEDVANCE, the makers of SYLVANIA General Lighting in the US and Canada, is launching its Brighter Days Ahead Campaign and asking, "What are you looking forward to in brighter days ahead?" For some, it's holding a postponed wedding or finally seeing a new grandchild for the first time. For others, it's inviting friends into their homes for game night or welcoming more patrons into their businesses. From today to July 31, 2021, people can go the campaign website to share what they're looking forward to this year. Five people in Canada and five people in the US will be picked in August to win $1,000 and a selection of the latest SYLVANIA General Lighting products to help brighten their days.   

Working Towards Brighter Days Ahead!
While it's true there are brighter days ahead, many are still battling the dark and LEDVANCE wants to help turn awareness into action. LEDVANCE is working with these leading mental health non-profits to share tips and resources on social media to support those who may be struggling.

• CAMH (Centre for Addiction and Mental Health) - Canada's largest mental health teaching hospital and one of the world's leading research centres, where Mental Health is Health. 
• NAMI (National Alliance of Mental Illness) - the largest grassroots mental health organization in the US dedicated to building better lives for the millions of Americans affected by mental illness. 
• Be the Light Campaign - a movement of volunteers creating events and random acts of kindness to spread hope, love & compassion. 

"Whether for their homes or businesses, we are honored that for over 100 years people have placed their trust in our SYLVANIA lighting products to illuminate their loved ones or customers' businesses. The past year has felt like a century, and everyone's family and workforce has been impacted by the global pandemic, causing enormous stress and anxiety. We want to help those struggling in the dark and celebrate there are brighter days ahead," said Charlie Harte, VP of Marketing and Customer Experience, LEDVANCE LLC.  

Brighter Days Ahead with SYLVANIA General Lighting 
Now, in the brighter days ahead, you can make your home and business even more comforting for loved ones, guests, and employees with better light for better living, including the following SYLVANIA General Lighting products.

• Available through distribution, SYLVANIA LED lamps and luminaires for electricians, contractors and facility managers are built on a legacy of over 100 years of lighting expertise and deliver beautiful illumination. They are easy to install and covered by LEDVANCE's award-winning warranty program so you can count on the LEDVANCE team being there. Many also let you select the lumens and/or color temperature you need all in one product. These all save you time so you can focus on things you want to do to brighten your day.  
• SYLVANIA TruWave^® Technology delivers LED light closest to the Sun's Natural Light, so you can see and feel better. Colors, whites and skin tones can look better in TruWave light, so you have an exceptional color experience. TruWave also reduces unnecessary blue light to help you fall asleep easier and reduce eye strain. 
• Available at the Home Depot in-store and online, SYLVANIA LightSHIELD Technology is an everyday light with germ-fighting benefits. When the LED bulb is switched on, the LightSHIELD coating is activated, which is safe for humans and pets. The natural circulation of the air brings germs, odors and any other organic compounds into contact with the coating where they are neutralized. 
• SYLVANIA SMART⁺ lighting can simplify your life with easy setup, controls and features, and style your life with beautiful illumination to suit your changing mood. 

For the latest on SYLVANIA lighting innovations for commercial and residential applications, visit www.sylvania.comor follow the makers of SYLVANIA General Lighting on social media on YouTube, Facebook, Twitter, Instagramand Pinterest.

ABOUT LEDVANCE LLC
With offices in more than 50 countries and business activities in more than 140 countries, LEDVANCE is one of the world's leading general lighting providers for professional users and end consumers. In North America, LEDVANCE LLC offers a wide range of SYLVANIA LED luminaires for various applications, intelligent lighting products for Smart Homes and Buildings, one of the largest LED lamps portfolios in the industry, and traditional light sources. The SYLVANIA brand leadership is a result of over 100 years of lighting experience and paves the way for future success. Further information can be found at www.sylvania.com.

Founder of Positive Psychology Martin Seligman awarded RCSI Honorary Doctorate
 

DUBLIN, May 28, 2021 -- Professor Martin Seligman has been awarded an Honorary Doctorate by RCSI University of Medicine and Health Sciences at the 2021 School of Medicine conferring ceremony. 

Professor Seligman, who is the Zellerbach Family Professor of Psychology and Director of the Positive Psychology Center at the University of Pennsylvania, is recognised as the founder of Positive Psychology as a field of scientific study. 

Through his pioneering work, he shifted the focus of psychology from the elimination of misery to the more empowering practices of gratitude, resilience and hope. He is also a recognised authority on interventions that prevent depression, and build strengths and well-being. 

He has written more than 350 scholarly publications and 30 books and his methods have been adopted widely across the world in education, healthcare and public policy. His most recent book The Hope Circuit, published in 2018, is an autobiography and memoir of his ideas, described as A Psychologist's Journey from Helplessness to Optimism.

RCSI established an Annual Honorary Doctorate Award in 2011 to recognise excellence and to provide inspiration to graduating students on their conferring day. The Honorary Doctorate of Science is the highest academic award given by the university and awardees are exceptional people who have made a difference to the world through education, research or service. 

Professor Cathal Kelly, RCSI CEO, said: “It is a great honour and privilege for RCSI that Professor Martin Seligman has accepted this Honorary Doctorate. Professor Seligman is a pioneer. As the founder of the field of positive psychology, he has dedicated his distinguished 55 year-long career to building our understanding of how our strengths, positive emotion, good relationships, meaning and flourishing shapes our lives and our health”.

“His influence permeates the culture of RCSI and inspired by his work we launched the world’s first academic centre for positive psychology and health in 2020. He is a most deserving recipient of this Honorary Doctorate”, added Professor Kelly. 

Led by Professor Ciaran O’Boyle, the RCSI Centre for Positive Psychology and Health applies the scientific principles of positive psychology and lifestyle medicine to enhance the health and happiness of people in Ireland and around the world. The Centre reflects RCSI’s commitment to Sustainable Development Goal 3, good health and well-being.

Next Tuesday (1 June) Professor Seligman will deliver an RCSI MyHealth guest lecture on Positive Psychology, Agency and Human Progress. The lecture airs at 2pm (Irish time). There is further information here.

ENDS

About RCSI University of Medicine and Health Sciences

RCSI University of Medicine and Health Sciences is a world-leading university for Good Health and Well-being. Ranked second in the world for its contribution to UN Sustainable Development Goal 3 in the Times Higher Education Impact Rankings 2021, it is exclusively focused on education and research to drive improvements in human health worldwide.

RCSI is an international not-for-profit university, headquartered in Dublin. It is among the top 250 universities worldwide in the World University Rankings (2021) and its research is ranked first in Ireland for citations. RCSI has been awarded Athena Swan Bronze accreditation for positive gender practice in higher education.

Visit the RCSI MyHealth Expert Directory to find the details of our experts across a range of healthcare issues and concerns. Recognising their responsibility to share their knowledge and discoveries to empower people with information that leads them to better health, these clinicians and researchers are willing to engage with the media in their area of expertise.

Roche Canada Announces Collaboration to Improve Access to Personalized Healthcare with Real World Evidence

BC Cancer, CPHIN and Roche Canada will co-create an evidence-generating framework to leverage real-world data and facilitate cost-effective access to targeted treatments for cancer patients

MISSISSAUGA, ON, May 28, 2021 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce a joint initiative with BC Cancer and the Canadian Personalized Healthcare Innovation Network (CPHIN) to co-create a real-world evidence (RWE) framework in British Columbia known as the PRecision Oncology Evidence Development in Cancer Treatment (PREDiCT). The PREDiCT initiative will generate and assess RWE, which may be used to help shape new sustainable reimbursement pathways for personalized cancer treatments.

This initiative marks a leading public-private collaboration in personalized healthcare in Canada and, if proven successful, represents an important milestone towards a healthcare system that leverages real-world and clinical trial data to provide the right care options for patients and inform policies that ensure cost-effective access.

The standard process for reimbursing cancer medicine is based on cost-effectiveness evaluations, and safety and efficacy data largely collected through clinical trials. However, RWE is becoming increasingly important to fill gaps in this data and capture insights throughout a patient's whole journey that can help guide clinical and reimbursement decision making. The demand for RWE by regulatory and reimbursement health authorities continues to grow, particularly for personalized cancer therapies that target rare mutations where traditional clinical trial evidence may be limited. The PREDiCT initiative aims to create a real-world data evidence-generation framework and elevate the use of RWE in informing healthcare decision-makers. The results could provide a new path forward for innovative therapies that may not fit the traditional reimbursement pathway – a critical step in ensuring cost-effective access to personalized cancer care for patients.

"PREDiCT has the potential to evolve the way health authorities and policy-makers interpret and use RWE in oncology decision-making, and potentially increase the number of targeted treatment options available to cancer patients across British Columbia, and eventually Canada," says Ronnie Miller, President and CEO, Roche Pharmaceuticals Canada. "In working together with BC Cancer and CPHIN, we can drive sustainable healthcare transformation leading to greater personalized care and better health, at a lower cost, for people and society."

"The core hope of PREDiCT is to change the BC Cancer healthcare data ecosystem and the way we make decisions," says Dr. Dean Regier, senior scientist, BC Cancer and PREDiCT co-principal investigator. "This initiative is moving forward with the intent of operationalizing learning healthcare systems for life cycle health technology assessment, with a view to generate real-world evidence to make better informed decisions about treatment efficacy, patient value, and cost-effectiveness."

The PREDiCT initiative also aims to generate and validate high-quality real-world data that examines the impact and value of comprehensive genomic profiling (CGP) to identify potential cancer mutations. "PREDiCT presents a great opportunity for BC Cancer to upgrade its molecular diagnostic offering to benefit more patients with clinically actionable information," explains Dr. Stephen Yip, pathologist, BC Cancer and PREDiCT co-principal investigator. "The improvement to the logistical and technical infrastructure of BC Cancer laboratories will accelerate the wider adoption of advanced genomic profiling in patients."

"The advantage of PREDiCT is that it enables generation of RWE for decision-making while prioritizing patient treatment and access to therapy," states Dr. Cheryl Ho, medical oncologist, BC Cancer and PREDiCT co-principal investigator. "This is an opportunity to facilitate access to a more personalized level of care for our patients with the longer-term vision of generating data that will help inform decision-makers," adds Dr. Howard Lim, medical oncologist, BC Cancer and PREDiCT co-principal investigator.

PREDiCT will initially be piloted at BC Cancer centres and CPHIN will convene healthcare partners to facilitate cross-provincial learning and scale the program beyond British Columbia. The ultimate goal is integrating a national framework to enable a more streamlined approach for patient access to cost-effective innovative treatments and technologies across many disease areas.

"Real-world evidence holds the potential to demonstrate how targeted treatments can improve patient care and clinical outcomes, but the current approach to leveraging RWE is fragmented and untapped," says Dr. Helen Chen, President, CPHIN. "Through this public-private partnership, PREDiCT paves the way for Canada-wide use of RWE at the healthcare decision-making level and unlock data insights that could lead to better patient outcomes."

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1931, Roche Canada is committed to searching for better ways to prevent, diagnose and treat diseases while making a sustainable contribution to society. The company employs more than 1,800 people across the country through its Pharmaceuticals division in Mississauga, Ontario and Diagnostics, as well as Diabetes Care divisions in Laval, Quebec.

Roche aims to improve patient access to medical innovations by working with all relevant stakeholders. Roche Canada is actively involved in local communities through its charitable giving and partnerships with organizations and healthcare institutions that work together to improve the quality of life of Canadians. For more information, please visit www.RocheCanada.com.

About BC Cancer

BC Cancer, a program of the Provincial Health Services Authority, is committed to reducing the incidence of cancer, reducing the mortality from cancer and improving the quality of life of those living with cancer. It provides a comprehensive cancer control program for the people of British Columbia by working with community partners to deliver a range of oncology services, including prevention, early detection, diagnosis and treatment, research, education, supportive care, rehabilitation and palliative care. For more information, visitwww.bccancer.bc.ca or follow us on Twitter@BCCancer.

About CPHIN

The Canadian Personalized Healthcare Innovation Network (CPHIN) is a pan-Canadian non-profit organization that brings together healthcare stakeholders and orchestrates initiatives that accelerate system transformation to enable personalized healthcare and improve health outcomes for Canadians. For more information go towww.cphin.ca or contact us at info@cphin.ca.

All trade-marks mentioned are the property of their respective owners.
© Copyright 2021; Hoffmann-La Roche Limited

SOURCE Roche Canada

The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) Largest Indie Player in Projected Billion-Dollar Water Market

NEW YORK, May 28, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) announces the availability of a broadcast titled, “M&A Activity Picks Up in F&B Sectors, Including Functional Water Assets Space.”

To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast

To view the full editorial, please visit: https://nnw.fm/Gs1C2

The megatrend the water majors are now trying to capture is the increasing consumer health consciousness towards enhanced water as a replacement for sugary drinks. The trend accelerated with people on lockdown buying enhanced water for a slew of reasons, but the fact remains that many consumers have now incorporated value-added waters as part of their lifestyle.

The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) is the largest independent player in the alkaline water market that is expected to reach $1 billion by next year. As the name implies, the Scottsdale, Arizona-based company specializes in producing drinking water with trace minerals and electrolytes and a higher pH, specifically 8.8, than regular drinking water, which has a neutral pH of 7.

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in six unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp, powder packs, oil tinctures, capsules and gummies. 

To learn more about the company, visit https://TheAlkalineWaterCo.com

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://nnw.fm/WTER

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. 

NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Khiron Life Sciences Reports First Quarter 2021 Financial Results

• Record revenues of $2.8 million in Q1 2021, a 49% increase from the prior year and 13% increase from Q4 2020 
• Record gross profits (before fair market value adjustments) of $1.1 million, a 171% improvement over Q4 2020 and record consolidated gross margin of 38% 
• Medical cannabis sales reach 20% of revenues, contributing over 45% of gross profits 
• More than 7,500 prescriptions filled in Q1 2021 and over 19,000 to date 
• First sales in Germany achieved in Q1 2021, with international sales representing approximately 10% of total Medical Cannabis Product revenues 
• Khiron real-world evidence is improving physician engagement, patient outcomes and strategic decision-making; initial results show significant benefits to quality of life as well as significant cost benefit to key insurance clients 
• $12.5 million in cash as of March 31, 2021 with working capital of $22.5 million

TORONTO, May 27, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announced today its financial results for the quarter ended March 31, 2021. These filings are available for review on the Company's SEDAR profile at www.sedar.com. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Summary of Key Financial Results

Q1 2021 operating highlights and subsequent events

• Insurance coverage in Colombia continues to be a catalyst for growth, with more than 7,500 prescriptions filled in Q1 2021 and over 19,000 prescriptions filled to date. With continued month-over-month growth, Q2 2021 continues to build on the achievements of Q1 2021. 
• Insurance coverage continues to improve patient access to medical cannabis, with the percentage of prescriptions issued and covered by insurance increasing from over 40% in Q4 2020 to over 60% in Q1 2021. 
• Returning medical cannabis patients in Colombia reached nearly 50% in Q1 2021, as compared to approximately 20% in Q3 2020, providing a more stable Medical Cannabis revenue base. 
• Khiron real-world evidence is improving physician engagement, patient outcomes and strategic decision-making. 
• Initial analysis of Khiron medical cannabis patient data for various neuropathic conditions shows a significant reduction in the intake of other medications (including opioids), improved quality of life, and material annual savings. Khiron's patient data continues to mount and will provide real-world evidence for pharmacoeconomic studies intended to support the Company's goal of reaching more patients. 
• Following the initial success of its Medellin satellite clinic, the Company opened five additional satellite clinics in Colombia in 2021, for a total of nine clinics including the three health centres in Bogota and six satellite clinics across the country. 
• Khiron recently partnered with the Colombia Cancer League to deliver an additional 3,000 medical cannabis patient consultations during the month of June, in collaboration with 21 leading medical institutions in 11 cities throughout Colombia. 
• Q1 2021 medical cannabis sales in Peru increased by over 175% compared to sales in 2020 (which began late in Q3 2020). Given the positive reception to Khiron products in Peru, the Company expects to open its first international Zerenia™ satellite clinic in Peru in the coming weeks. 
• The Company plans to deploy its Zerenia™ medical cannabis clinic and telehealth strategy in Mexico and Brazil, building on the success of its vertical integration strategy in Colombia. 
• In March 2021, the Company successfully exported its Colombian-registered cannabis strains, in the form of live clones, from Colombia to Europe. 
• In March 2021, Khiron commenced sales in Germany with the successful delivery of EU-GMP medical cannabis products. Khiron 1/14 (High CBD flower) has been used to treat indications such as anxiety, substance-use disorder and migraines. 
• The Company continues to advance its operations in the UK. In April 2021, the Company introduced Khiron 1/14 (High CBD flower) in addition to 5-gram jars of flower products. In addition, the Company's medical cannabis e-learning certification, Khiron Academy, recently received accreditation for Continuing Professional Development credits in the UK. 

Discussion of Operations for the Three Months Ending March 31, 2021  
During the first quarter of 2021, the Company reported record revenues of $2.8 million, a 49% increase as compared to Q1 2020 due to normalized clinic operations and the growth of medical cannabis sales. Relative to Q4 2020, first quarter revenues increased 13% due to a 141% increase in Medical Cannabis Product sales, which reached $563,000 in the quarter, as the Company benefited from medical cannabis insurance coverage in its core market of Colombia. 

At $1.1 million, or 38% of revenues, the Company achieved record gross profits due to increasing Medical Cannabis Product sales and margin improvements within the Health Services segment. Notably, Medical Cannabis margins remained high at 90% of revenues, while Health Service margins increased to 26% of revenues in Q1 2021, from 7% in Q4 2020. 

In Q1 2021, the Company incurred lower general and administrative costs as compared to Q1 2020 due cost cutting measures implemented in the second quarter of 2020 and the devaluation of the Colombian peso. Overall, the Company recorded a net loss of $5.5 million in Q1 2021, which compares to a net loss of $9.2 million in Q1 2020 and $2.4 million in Q4 2020.  Adjusted EBITDA losses of $4.0 million compared to losses of $5.9 million in Q1 2020 due to ongoing cost management initiatives and improved sales and margins. 

Management Commentary 
"Q1 was a record quarter for the company, in terms of both revenues and gross profits, driven by strong results in our Medical Cannabis segment, which achieved another quarter of more than 100% growth. Insurance coverage for medical cannabis in Colombia continues to have a positive impact, providing greater revenue stability as returning patients reached 50% of medical cannabis patient volumes in Q1. I am also happy to report that our gross profits were well above Q4 2020, driven by strong clinic performance and growth from our vertical integrated medical cannabis strategy. As of April, prescriptions in Colombia were already equal to 44% of those filled in Q1, positioning us for another record quarter in Q2," comments Alvaro Torres, Chief Executive Officer and Director of the Company.

"In Europe, our world-class team continues to execute, recently delivering first sales in Germany and a strategic partnership with Cellen Therapeutics, a leader in digital healthcare in the UK and fellow founding member of Project Twenty21. We also received UK CPD accreditation for our global medical cannabis education platform, Khiron Academy, and imported the first ever live cannabis clones from Colombia to Europe. Collectively, these achievements will help us deliver on our mission of improving patients' lives by increasing access to medical cannabis products both at home and abroad," continued Alvaro Torres.

Webcast Details 
Khiron invites individual and institutional investors, as well as advisors and analysts, to attend a webcast and Q&A to discuss the Company's Q1 2021 financial statements and further activities.

DATE: May 28, 2021
TIME: 10:00am ET/7:00am PT
PRESENTERS: Alvaro Torres, Khiron Chief Executive Officer and Director, Joel Friedman, Khiron Chief Financial Officer, and Chris Naprawa, Chairman of Khiron's Board of Directors 
FORMAT: Live 30 minutes presentation & Q&A session 
REGISTER LINK: 
https://event.on24.com/wcc/r/3196006/0652A31C731C234FE0C2F998FCEBFFEB

About Khiron Life Sciences Corp. 
Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America, and operational activity in Europe and North America. Khiron is the leading medical cannabis provider in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution and sales, and international export of both low and high THC medical cannabis products. The Company has filled medical cannabis prescriptions in Colombia, Peru, Germany and the United Kingdom, and is positioned to commence sales in Mexico and Brazil in 2021.

Leveraging wholly-owned medical clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty. Its Wellbeing unit launched the first branded CBD skincare brand in Colombia, with KuidaTM now marketed in multiple jurisdictions in Latin America, the US and United Kingdom. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.

Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.

Cautionary Notes

Forward-Looking Statements 
This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Investor Contact: 
Paola Ricardo
E: investors@khiron.ca 
T: +1 (647) 556-5750

Media Contact:
Elsa Navarro
Vice President, Communications
E: enavarro@khiron.ca

Khiron Europe:
Tejinder Virk
Europe President
E: tvirk@khiron.ca

SOURCE Khiron Life Sciences Corp.

Tap into Trauma’s Emotional Energy and Use it to Power a Fulfilling Future

Los Angeles, CA, May 27, 2021 — Trauma doesn’t have to lead to a lifetime of weakness or hardship. In fact, trauma can lead to greater resilience and higher levels of achievement than we thought possible. 

Dr. Randall Bell, widely considered the world’s top authority in the field of post-traumatic thriving, shares a process for not only surviving trauma but also thriving in the aftermath in his latest book, Post-Traumatic Thriving: The Art, Science, & Stories of Resilience.

“It can’t happen to me” is one of life’s greatest lies, he notes. But if or when it does happen, it’s possible to harness the emotional energy generated by the traumatic event — whether it was losing a loved one, surviving a natural disaster or being a victim of violence — and use it to heal and grow in entirely new directions.

“How do you take that energy from the trauma and tap into it to do something really remarkable that you wouldn’t have done otherwise?” asks Dr. Bell.

In Post-Traumatic Thriving, he shares stories of real people (many of them, like Leo Fender, are familiar) who have done exactly that, including: 

• A deaf man with a glass eye invented the electric guitar and became a household name, remarkably wealthy and most importantly, happy. 

• A convicted murderer took responsibility for the damage he caused, graduated with honors from college, became a minister and turned around the hearts of the most hardened criminals.

• A girl born with cerebral palsy landed the world’s first starring role on national television and spoke at the White House three times.

• A woman hid in a basement for years and lost her entire family in the Holocaust. She eventually found true love and paints stunning artwork.

• The sister of a murder victim helped millions of women in toxic domestic relationships.

• A woman’s car crash resulted in an addiction to prescription drugs, a divorce, a loss of her children and a cot in a homeless shelter. She has rebuilt it all back and more.

• A man set to go to the Olympics had his hopes dashed by Jimmy Carter and went on to build a worldwide business empire.

Dr. Bell juxtaposes outcomes of scientific studies with these stories to reveal common denominators among “thrivers.” He divides his insights into three sections: The Dive Stage, The Survive Stage and The Thrive Stage, and outlines a step-by-step process toward authentic healing. 

As a socio-economist, Dr. Randall Bell has consulted on more disasters on earth than anyone in history. His clients include the Federal Government, State Governments, International Tribunals, major corporations and homeowners. Dr. Bell believes that “the problem is not the problem — the problem is how we react to the problem.” 

Often called the “Master of Disaster,” Dr. Bell is squarely focused on authentic recovery and resilience. His research has been profiled on major television shows and featured in numerous magazines and the international media. More information can be found at www.posttraumaticthriving.com. 

Post-Traumatic Thriving: The Art, Science, & Stories of Resilience

Publisher: Core IQ Press

ISBN 978-0-9967931-7-9

Available from Amazon.com and all bookstores

Switch Health Partners with Voyce to Improve Patient-Focused Healthcare in More Than 235 Languages and Dialects

TORONTO, May 27, 2021 /CNW/ - Switch Health today announced it is offering at-home and mobile COVID-testing services in more than 235 languages and dialects, including American Sign Language, through a partnership with Voyce. Voyce is a technology company that provides real-time, on-demand access to professional medical interpreters by video or audio connection.

Switch Health provides Canadians with its safe and innovative end-to-end at-home and mobile COVID-testing solution through its at-home collection kits, at-home virtual consults with trusted healthcare professionals, and digital results reporting through its proprietary telehealth platform and partner laboratories. 

"Our partnership with Voyce demonstrates another important step towards accessible, patient-focused, digital healthcare," said Dilian Stoyanov, CEO of Switch Health. "With Voyce, Switch Health will continue to transform the way Canada delivers healthcare through cutting-edge telehealth solutions that serve patients in the comfort of their home or workplace, and in the language they are most comfortable communicating in." 

"According to the 2016 census, more than 20% of people living in Canada speak a primary language other than English or French," said Andrew Royce, CEO of Voyce. "Voyce technology strives to empower all patients by making healthcare accessible in their preferred language. We are proud to support Switch Health with professional medical interpreters available on demand."

The partnership with Voyce means that more patients will have access to service in the language of their choice and, because the language interpretation is provided in near real-time, it will reduce waiting times for these patients in need. 

"Today's announcement is another example of how we're building on partnerships with leading companies, like Purolator, Uber, and some of Canada's top laboratories to enhance our ability to provide Canadians with reliable next generation testing tools that they can use at home, no matter where they live in Canada, and in the language of their choice," added Stoyanov.

About Switch Health

Switch Health Holdings Inc. (Switch Health) is an industry leader that is transforming how healthcare is delivered in Canada through cutting edge decentralized next generation diagnostics and patient-focused digital solutions. Switch Health has developed an end-to-end, innovative, and accessible testing-solution in Canada's fight against COVID-19, with its at-home and mobile collection kit to test Canadians safely, rapidly, and reliably for COVID-19. Switch Health offers its gold standard of rapid and PCR testing in over 200 languages from the comfort of peoples' homes or workplaces, with the guidance of trusted healthcare professionals and the delivery of results through some of Canada's top laboratories. 

About Voyce

Voyce is a technology company deeply committed to helping people in need facing language barriers, enabling them to easily and quickly communicate and get help. Its professional and qualified language interpreters provide interpretation across a variety of technology and telehealth platforms in 235+ languages and dialects, including American Sign Language. Across Canada, the U.K., the U.S. and globally, Voyce supports thousands of sessions a day providing language assistance to those in need. 

SOURCE Switch Health Inc.

Ontario government launches Pathways to Safety: Ontario’s Strategy in Response to the Final Report into Missing and Murdered Indigenous Women and Girls

Thunder Bay, ON, May 27, 2021 (GLOBE NEWSWIRE) -- 

The Ontario Native Women’s Association (ONWA) and Ganohkwasra Family Assault Support Services acknowledges and honours the thousands of Indigenous women and girls taken from us by violence. Many of these women were mothers whose children have now been forced to navigate their lives without them. And so, we also honour and acknowledge the children, families, friends, and loved ones of Missing and Murdered Indigenous Women and Girls (MMIWG).

ONWA and Ganohkwasra also recognizes the awareness raising efforts of grassroots organizers, community activists, and Indigenous women’s organizations who took up their leadership roles and responsibilities and successfully advocated for the National Inquiry. The work that collectively needs to be done is to prevent all forms of violence for future generations of Indigenous women and girls.

“As the bearers of the future generations of our peoples, Indigenous women, mothers, are physically and symbolically the source of resistance against those who would see us disappear.” – Dr. Dawn Lavell-Harvard, Board President, ONWA

A wholistic, community-based, cross-jurisdictional approach is key to ending this tragedy. Partnership with the Indigenous Women’s Advisory Council and Indigenous partners, alongside engagement with Indigenous women, survivors and families was fundamental to developing Ontario’s strategy, and will be integral to its implementation.

“So many initiatives that have the power to lead our Indigenous Women and Girls to a safe and secure outcome are revealed in this document being released today.” – Sandra Montour, Co-Chair, Indigenous Women’s Advisory Council

The Indigenous Women’s Advisory Council has developed a placemat that is a companion to Ontario’s Response. The placemat illustrates the structure and recommendations of Ontario's MMIWG response, while also incorporating cultural elements. To view the placemat go to: www.onwa.ca/learning-resources-mmiwg

Ontario’s strategy aligns with what Indigenous women have been asking for because they listened to our voices, expertise, guidance, and recommendations. When our truths are listened to and governments respect the recommendations of Indigenous women, we begin to build a foundation for change.

While Ontario’s response represents progress, we must remember that a lot of work still lays ahead of us. It is imperative that this plan remains accountable to Indigenous women and their organizations, and that any proposed investments in Ontario’s response are met and upheld, with particular focus on the immediate safety needs of Indigenous Women, and healing for Indigenous women, families, and communities.

The Ontario Native Women’s Association and Ganohkwasra Family Assault Support Services look forward to continuing to work as a collective force. Sharing a vision where Indigenous women and girls live in safety and security, free from violence and exploitation, supported by accountable and ongoing systemic and structural change in the province.

To view the report go to: Ontario.ca/PathwaysToSafety (English), or Ontario.ca/parcoursverslasecurite(French).

What Kinds of Food Can Supplement Your Exercise?

Exercise and diet go hand in hand when it comes to maintaining a healthy lifestyle. If you want to get the most from each workout and live the healthiest life possible, you should be eating the right foods to supplement your fitness routine. By eating more of these five healthy foods, you’ll likely have an easier time reaching your fitness goals as you continue to exercise.

Whole Grain Wheat

Wheat from whole grains can be utilized by the body for energy better than crappy bleached white wheat grain. Whole grain wheat offers carbohydrates that can act as fuel sources so that you stay more energized through tough and long workouts. Bread or cereal that’s made from whole grain wheat can be eaten before workouts to get the maximum benefits.

High Protein Foods

There are many high-protein foods that can help you build more muscle. Poultry and red meat are among the best food sources for protein, but you can also increase your protein intake by eating more fish, such as tuna or salmon. Eggs are also an excellent source of protein. If you’re a vegetarian or vegan, you can get more protein in your diet by eating plenty of beans, chickpeas, and peanuts.

Supplement Bars

There are many supplement bars on the market that can be eaten as snacks to boost your workout routine. Protein bars are never in short supply, but you can also find antioxidant bars that help protect the body from free radicals, which can damage cells and decrease your fitness. Many of the best supplement bars contain natural ingredients and are free of refined sugar, gluten, and soy.

Leafy Greens

You probably already know the importance of eating vegetables, but eating more leafy greens can have even more health benefits. The good nitrates that are found in leafy green vegetables are known to increase energy and give the muscles more of the oxygen and nutrients that they need to perform better during challenging workouts. Cabbage, spinach, and kale are among the best leafy greens for nutrition.

Fruits

Certain fruit types are known to be especially beneficial for exercise. By eating a pear, an apple, or some grapes before a workout, you can give your body more of the fuel that it needs to stay energized. Bananas, berries, and cherries are among the best fruits to eat after a workout and can aid in your recovery periods.

These foods should be part of any workout plan if you want to get the fittest and live the healthiest. Adding more of these foods to your diet shouldn’t be difficult, and you’ll likely notice a big improvement in your performance when it’s time to exercise.